Protalix BioTherapeutics, Inc. (PLX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 63 | 38 | 48 | 65 | 53 | 53 | 81 | 82 |
| Operating profit | $m | -5 | 23 | ||||||
| Net profit | $m | -7 | -28 | -15 | 8 | 3 | -7 | 19 | 16 |
| EPS reported | $ | -0.08 | 0.23 | ||||||
| Operating cashflow per share | $ | -0.15 | 0.12 | ||||||
| Capex per share | $ | 0.02 | 0.03 | ||||||
| FCF per share | $ | -0.17 | 0.10 | ||||||
| Free cash flow | $m | -14 | 8 | ||||||
| Net debt | $m | -30 | -41 | ||||||
| Book value equity | $m | 48 | 71 | ||||||
| Book value per share | $ | 0.61 | 0.86 | ||||||
| Number of shares | m | 78.55 | 82.56 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 11.64 | ||||||
| P/B LTM | x | 2.93 | 1.98 | ||||||
| P/S LTM | x | 2.68 | 1.75 | ||||||
| P/FCF LTM | x | -10.37 | 18.44 | ||||||
| EV/EBITDA LTM | x | -45.74 | 5.14 | ||||||
| EV/Sales LTM | x | 2.56 | 1.99 | ||||||
| Earnings Yield LTM | % | -4.67% | +8.59% | ||||||
| FCF Yield | % | -9.64% | +5.42% | ||||||
| Quality | |||||||||
| ROE | % | -13.69% | +31.61% | ||||||
| ROIC | % | -9.61% | +23.33% | ||||||
| Operating margin | % | -10.43% | +28.89% | ||||||
| Gross margin | % | +47.85% | +69.20% | ||||||
| FCF/Sales | % | -25.84% | +9.51% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +528.42% | ||||||
| Sales Growth YoY | % | -1.23% | +50.97% | ||||||
| Net Income Growth YoY | % | - | +546.15% | ||||||
| FCF Growth | % | - | +3.73% | ||||||
| Operating Profit Growth | % | - | +494.61% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.64 | 0.83 | ||||||
| Net Debt/EBITDA | x | 2.15 | -0.69 | ||||||
| EBIT/Net interest | x | -4.62 | 18.63 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.63 | -0.57 | ||||||
| Gross debt/equity | x | 0.17 | 0.13 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Protalix BioTherapeutics, Inc. (PLX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free